Replimune's Lead Drug Accepted for FDA Review
Replimune (REPL) announced that the FDA has accepted its resubmitted marketing application for RP1 and will convene an advisory committee to review it. The company’s shares fell in premarket trading following this news.
Tickers: $REPL